Use of basiliximab in pediatric liver transplantation for Langerhans cell histiocytosis.
Pediatr Transplant
; 7(3): 247-51, 2003 Jun.
Article
em En
| MEDLINE
| ID: mdl-12756053
ABSTRACT
This report describes a 16-month-old girl with multi-system Langerhans cell histiocytosis (LCH), who developed end-stage liver disease despite intensive chemotherapy. She underwent a liver transplant at 28 months of age while receiving maintenance chemotherapy for bony lesions. In view of previous reports of a high incidence of acute cellular rejection and post-transplant lymphoproliferative disease (PTLD) in children transplanted for LCH, basiliximab was added to the post-transplant immunosuppression regime of tacrolimus and prednisolone. Sixteen months post-transplant, she has had no episodes of acute rejection or PTLD and her LCH has remained in remission. Current literature regarding liver transplantation (LTx) for LCH and the use of basiliximab in pediatric LTx is reviewed.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Histiocitose de Células de Langerhans
/
Transplante de Fígado
/
Imunossupressores
/
Anticorpos Monoclonais
Tipo de estudo:
Etiology_studies
Limite:
Female
/
Humans
/
Infant
Idioma:
En
Revista:
Pediatr Transplant
Assunto da revista:
PEDIATRIA
/
TRANSPLANTE
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Reino Unido